Genome Analysis Study to Aid Diagnosis of Rare Developmental Disorders
By LabMedica International staff writers Posted on 06 Jan 2015 |
First results from a study that will eventually incorporate complete genome analysis of 12,000 families in the United Kingdom and the Republic of Ireland have revealed 12 novel genes associated with rare and difficult to diagnose developmental disorders.
The Deciphering Developmental Disorders (DDD) study, which is underwritten primarily by the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) was designed to capitalize on the latest genetic techniques in order to help doctors understand the basis for developmental disorders. The program has brought together clinicians in the 24 Regional Genetics Services throughout the United Kingdom and researchers at the Wellcome Trust Sanger Institute, which played a leading role in sequencing the human genome. The DDD study involves experts in clinical, molecular, and statistical genetics as well as in ethics and social science.
The first paper to be published under the auspices of the DDD program reported results from a study of 1,133 children with severe, undiagnosed developmental disorders, and their parents, using a combination of exome sequencing and array-based detection of chromosomal rearrangements. The investigators reported discovering 12 novel genes associated with developmental disorders. These newly implicated genes increased by 10% (from 28% to 31%) the proportion of children that could be diagnosed. All of the newly diagnosed developmental disorders were caused by de novo mutations, which were present in the child but not in their parents' genomes.
DDD's nationwide secure data-sharing network made it possible to find and compare these rare disorders. For example, for four of the 12 newly identified genes, identical mutations were found in two or more unrelated children living hundreds of miles apart. In another example, two unrelated children, both with identical mutations in the PCGF2 (Polycomb group RING finger protein 2) gene, which is involved in regulating genes important in embryo development, were found to have strikingly similar symptoms and facial features. This discovery enabled the certification of a new, distinct dysmorphic syndrome.
"The DDD study has shown how combining genetic sequencing with more traditional strategies for studying patients with very similar symptoms can enable large-scale gene discovery," said contributing author Dr. John Burn, professor of clinical genetics at Newcastle University (United Kingdom). "This data-set becomes more effective with each diagnosis and each newly identified gene."
The study was published in the December 24, 2014, online edition of the journal Nature.
Related Links:
Wellcome Trust Sanger Institute
Newcastle University
The Deciphering Developmental Disorders (DDD) study, which is underwritten primarily by the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) was designed to capitalize on the latest genetic techniques in order to help doctors understand the basis for developmental disorders. The program has brought together clinicians in the 24 Regional Genetics Services throughout the United Kingdom and researchers at the Wellcome Trust Sanger Institute, which played a leading role in sequencing the human genome. The DDD study involves experts in clinical, molecular, and statistical genetics as well as in ethics and social science.
The first paper to be published under the auspices of the DDD program reported results from a study of 1,133 children with severe, undiagnosed developmental disorders, and their parents, using a combination of exome sequencing and array-based detection of chromosomal rearrangements. The investigators reported discovering 12 novel genes associated with developmental disorders. These newly implicated genes increased by 10% (from 28% to 31%) the proportion of children that could be diagnosed. All of the newly diagnosed developmental disorders were caused by de novo mutations, which were present in the child but not in their parents' genomes.
DDD's nationwide secure data-sharing network made it possible to find and compare these rare disorders. For example, for four of the 12 newly identified genes, identical mutations were found in two or more unrelated children living hundreds of miles apart. In another example, two unrelated children, both with identical mutations in the PCGF2 (Polycomb group RING finger protein 2) gene, which is involved in regulating genes important in embryo development, were found to have strikingly similar symptoms and facial features. This discovery enabled the certification of a new, distinct dysmorphic syndrome.
"The DDD study has shown how combining genetic sequencing with more traditional strategies for studying patients with very similar symptoms can enable large-scale gene discovery," said contributing author Dr. John Burn, professor of clinical genetics at Newcastle University (United Kingdom). "This data-set becomes more effective with each diagnosis and each newly identified gene."
The study was published in the December 24, 2014, online edition of the journal Nature.
Related Links:
Wellcome Trust Sanger Institute
Newcastle University
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans